Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Cash from Operations (2024 - 2025)

Xilio Therapeutics' Cash from Operations history spans 2 years, with the latest figure at 17495000.0 for Q3 2025.

  • For Q3 2025, Cash from Operations fell 27.96% year-over-year to 17495000.0; the TTM value through Sep 2025 reached 17151000.0, changed N/A, while the annual FY2024 figure was 18378000.0, 73.22% up from the prior year.
  • Cash from Operations for Q3 2025 was 17495000.0 at Xilio Therapeutics, down from 14477000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 28978000.0 in Q1 2025 and bottomed at 17495000.0 in Q3 2025.